Previously, numerous experiments showed that Aβ42 levels decreased in Cerebrospinal fluid (CSF) of patients with AD, and that the tau and p-tau levels increased compared with matched controls [8,9,10,11,12,13,14]. The gene discussed is MAPT; the disease is Alzheimer disease.